London, UK and Carlsbad, CA, USA – 28 June 2021 – DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, has appointed Alison Howie as Vice President of Commercial with immediate effect.
Alison brings over 25 years of experience in the life sciences and diagnostics industries, during which she has held a number of senior marketing and business development roles. Joining DNAe’s senior management team, she will take the lead on commercial and market-orientated functions.
Alison worked for over eight years at Thermo Fisher Scientific, where she held leadership positions including Vice President of Marketing & Product Development and Vice President of R&D and Business Development for the company’s Microbiology business.
As well as her large multinational experience Alison has also spent time as an executive and leader in small and medium sized enterprises, including most recently two years as Chief Commercial Officer and Chief Product Officer at Ixico, a specialist provider of data analytics to Life Science clients. She has also worked as a managing consultant at PA Consulting, advising a range of clients on innovation, product launch and commercial scale-up.
Alison holds a BSc in Chemistry and an executive MBA from the London Business School.
Commenting on Alison’s appointment, Samuel Reed, CEO of DNAe, said: “We are happy to welcome Alison. She has a fantastic track record of leadership, business development and strategic insight in our industry, further strengthening our great team as we take the next exciting step in our journey to bring our LiDia-SEQ™ diagnostic platform to patients.”
Alison Howie commented: “I’m excited to be joining DNAe at a time of rapid company development and I look forward to helping to build on its success to date, leading the company’s commercial activities to deliver on its promise to bring state-of-the-art diagnostic innovation to the point of need.”